Risk factors identified for acute pancreatitis that can disrupt leukemia treatment

April 25, 2016, St. Jude Children's Research Hospital
"Mary Relling, PharmD, is Chair of the Pharmaceutical Sciences Department at St. Jude, and Chengcheng Liu, Ph.D., is a postdoctoral fellow in the Pharmaceutical Sciences Department." Credit: St. Jude Children's Research Hospital / Peter Barta

Researchers have identified a rare genetic variation associated with a dramatically increased risk of severe acute pancreatitis in acute lymphoblastic leukemia (ALL) patients treated with the chemotherapy agent asparaginase. St. Jude Children's Research Hospital led the study, which appears today in the Journal of Clinical Oncology.

Asparaginase is an important agent used to treat ALL, but is also a major cause of acute pancreatitis in ALL patients. The painful and sometimes life-threatening condition occurs in 2 to 18 percent of the patients, complicating their treatment and threatening their chances of being cured. If the association between a rare variation in the CPA2 gene and asparaginase-related pancreatitis is confirmed, the results could help identify patients who are candidates for chemotherapeutic regimes that do not include the drug.

"In this study we identified several independent risk factors for asparaginase-induced pancreatitis and also gained insight into the mechanism responsible for this serious treatment complication," said corresponding author Mary Relling, Pharm.D., chair of the St. Jude Department of Pharmaceutical Sciences. "Understanding the risk factors for is important because in patients who can tolerate the drug, asparaginase reduces the likelihood that ALL patients will relapse."

Researchers also identified an association between Native American ancestry and an increased risk of pancreatitis following asparaginase therapy. Ancestry was genetically defined in this study, with higher Native American ancestry in Hispanic ALL patients. For every 10 percent increase in Native American ancestry, the risk of pancreatitis increased 20 percent.

The study confirmed previous reports that older age as well as higher doses and longer duration of asparaginase therapy were associated with a greater risk of pancreatitis. Researchers found that the risk in ALL patients was higher in teenagers than in young children.

The research included 5,398 ALL patients ranging from infants to young adults who were treated in clinical trials organized by St. Jude or the Children's Oncology Group, a federally funded pediatric cancer clinical trials network. The study included 188 patients who developed pancreatitis at least once during ALL therapy. The project was the largest yet to identify risk factors for asparaginase-related pancreatitis in ALL patients.

The search for involved checking patient DNA for more than 920,000 gene variants. Researchers also sequenced 283 genes, including genes associated with ALL risk and treatment outcome plus genes linked to an elevated risk of pancreatitis in patients with different health problems.

Two study participants each carried one copy of a CPA2 variant that yield a truncated version of the enzyme proCPA2. Both patients developed severe pancreatitis within weeks of receiving their first dose of asparaginase. "That suggests patients with this rare variant cannot tolerate the drug long enough to benefit from treatment. For these , ALL treatment regimens that do not depend on asparaginase may be preferable," Relling said. Researchers estimated about 9 in 100,000 individuals carry the suspected high-risk CPA2 variant.

Other more commonly occurring gene variants identified in this study provided insights into the mechanisms underlying asparaginase-associated pancreatitis. The variants were more modestly associated with pancreatitis in this study. The variations included genes involved in purine metabolism and the cytoskeleton, which helps cells maintain their shape.

Explore further: Pancreatitis often caused by gallstones—also statins increase risk

More information: Journal of Clinical Oncology, DOI: 10.1200/JCO.2015.64.5812

Related Stories

Pancreatitis often caused by gallstones—also statins increase risk

December 7, 2015
Idiopathic pancreatitis is often caused by small gallstones that are difficult to observe prior to surgery, shows a study from the University of Eastern Finland. Small gallstones were found in surgery from two out of three ...

Young adults with ALL have encouraging survival with pediatric regimen

December 7, 2015
Using a pediatric chemotherapy regimen to treat young adults with acute lymphoblastic leukemia (ALL) significantly improved their outcomes compared to what has historically been achieved with 'adult' treatment protocols, ...

Recurrent acute and chronic pancreatitis in children has high disease burden, health care costs

January 4, 2016
The burden of recurrent acute and chronic pancreatitis in children may be higher than previously thought, with high costs related to repeated hospitalizations, report a pair of studies in the Journal of Pediatric Gastroenterology ...

Rectal indomethacin doesn't prevent post-ERCP pancreatitis

April 7, 2016
(HealthDay)—For patients undergoing endoscopic retrograde cholangiopancreatography (ERCP), rectal indomethacin does not prevent the development of post-ERCP pancreatitis (PEP), according to a study published in the April ...

Smoking, alcohol, gene variant interact to increase risk of chronic pancreatitis

January 8, 2015
Genetic mutations may link smoking and alcohol consumption to destruction of the pancreas observed in chronic pancreatitis, according to a 12-year study led by researchers at the University of Pittsburgh School of Medicine. ...

Less painful drug delivery for pediatric leukemia patients is safe, effective

December 10, 2013
Children with acute lymphoblastic leukemia (ALL), the most common form of pediatric cancer, can safely receive intravenous infusions of a reformulated mainstay of chemotherapy that has been delivered via painful intramuscular ...

Recommended for you

Combining three treatment strategies may significantly improve melanoma treatment

December 12, 2018
A study by a team led by a Massachusetts General Hospital (MGH) investigator finds evidence that combining three advanced treatment strategies for malignant melanoma—molecular targeted therapy, immune checkpoint blockade ...

Lethal combination: Drug cocktail turns off the juice to cancer cells

December 12, 2018
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth—this was discovered by researchers from the University of Basel's Biozentrum two years ago. In a follow-up study, ...

Researchers use computer model to predict prostate cancer progression

December 12, 2018
An international team of cancer researchers from Denmark and Germany have used cancer patient data to develop a computer model that can predict the progression of prostate cancer. The model is currently being implemented ...

An integrated approach to finding new treatments for breast cancer

December 12, 2018
Unraveling the complexity of cancer biology can lead to the identification new molecules involved in breast cancer and prompt new avenues for drug development. And proteogenomics, an integrated, multipronged approach, seems ...

New insight into stem cell behaviour highlights therapeutic target for cancer treatment

December 12, 2018
Research led by the University of Plymouth and Technische Universität Dresden has identified a new therapeutic target for cancer treatment and tissue regeneration – a protein called Prominin-1.

Pushing closer to a new cancer-fighting strategy

December 11, 2018
A molecular pathway that's frequently mutated in many different forms of cancer becomes active when cells push parts of their membranes outward into bulging protrusions, Johns Hopkins researchers report in a new study. The ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.